Target intelligence / Profile preview

Chimeric antigen receptor (CAR) (CAR)

Target
CAR
Molecular classification
Receptor, Synthetic fusion protein, Immunoreceptor
01

Overview

A Chimeric Antigen Receptor (CAR) is a synthetic, engineered transmembrane protein designed to provide immune effector cells, typically T cells, with the ability to recognize and eliminate specific target cells, such as cancer cells, independently of the major histocompatibility complex (MHC) (June & Sadelain, 2018, NEJM). A CAR typically consists of an extracellular antigen-binding domain (usually a single-chain variable fragment or scFv), a hinge region, a transmembrane domain, and one or more intracellular signaling domains, such as CD3-zeta and costimulatory domains like 4-1BB or CD28 (Maus et al., 2014, Blood). By bypassing MHC restriction, CARs allow T cells to target a wide range of surface antigens that are not normally processed and presented (NIH NCI, 2024). In clinical practice, CAR-T cell therapies have revolutionized the treatment of B-cell malignancies by targeting antigens like CD19 and BCMA (FDA, 2023). However, the potent activation of the immune system by CAR-expressing cells can lead to significant toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) (Neelapu et al., 2018, Nat Rev Clin Oncology). Ongoing research focuses on expanding CAR technology to solid tumors and improving safety through switchable or logic-gated CAR designs to minimize off-tumor effects (Labanieh et al., 2018, Nature Biomedical Engineering).

Other names
Artificial T cell receptorChimeric T cell receptorChimeric immunoreceptorSynthetic T cell receptor
02

Mechanism of action

Chimeric antigen receptors (CARs) redirect T-cell specificity toward a surface antigen in an MHC-independent manner. Upon binding of the extracellular antigen-binding domain (scFv) to the target, the intracellular signaling domains (CD3-zeta and costimulatory domains like 4-1BB or CD28) initiate a signaling cascade that leads to T-cell activation, cytokine production, and cytotoxic degranulation, resulting in the lysis of the target cell (June & Sadelain, 2018, NEJM; Maus et al., 2014, Blood).

03

Biological functions

Immune responseSignal transductionCell-mediated cytotoxicityT-cell activation
04

Disease associations

CancerB-cell lymphomaAcute lymphoblastic leukemiaMultiple myelomaAutoimmune disease
05

Safety considerations

Cytokine release syndrome (CRS) [StatPearls, 2023]Immune effector cell-associated neurotoxicity syndrome (ICANS) [StatPearls, 2023]On-target off-tumor toxicity [Morgan et al., 2010, Molecular Therapy]B-cell aplasia [Kochenderfer et al., 2012, Blood]Hypogammaglobulinemia
06

Interacting drugs

Tisagenlecleucel

6 more in the full profile.

07

Biomarkers

Target antigen expression (e.g., CD19, BCMA) [Sadelain et al., 2017, Nature]Serum Interleukin-6 (IL-6) [Neelapu et al., 2018, Nat Rev Clin Oncol]C-reactive protein (CRP) [Neelapu et al., 2018]Ferritin [Neelapu et al., 2018]CAR-T cell transgene levels via qPCR [Mueller et al., 2017, Blood]

Beyond the preview

Go deeper on Chimeric antigen receptor (CAR) (CAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chimeric antigen receptor (CAR) (CAR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call